SOURCE: AXM Pharma, Inc.

August 25, 2005 09:00 ET

AXM Pharma Announces Promotion With 7-Eleven for AXM'S Sunkist Product in Hong Kong

LAS VEGAS, NV -- (MARKET WIRE) -- August 25, 2005 -- AXM Pharma, Inc. (AMEX: AXJ) announced today that it had launched an advertising and promotional campaign with 7-Eleven for the Company's dissolve-in-the-mouth films. The campaign will provide 7-Eleven's customers with a special redemption for a trial pack Sunkist Vitamin C dissolve in mouth strips marketed as Sunkist CLeafs.

7-Eleven has initiated a print advertising campaign in conjunction with the redemption. The 7-Eleven chain has over 640 outlets in Hong Kong. The promotion began August 23, 2005. 7-Eleven, Inc., its licensees and affiliates, operate more than 27,900 7-Eleven and other convenience stores in Japan, Australia, Mexico, Taiwan, Singapore, Canada, the Philippines, Sweden, Denmark, South Korea, Thailand, Norway, Turkey, Malaysia, China and the U.S. territories of Puerto Rico and Guam. Pictures of the promotion and campaign can be found at www.axmpharma.com.

"We are extremely pleased to have our products featured in the 7-Eleven stores. With the anticipated success, we plan to expand our relationship with the chain and to initiate similar types of programs throughout the Asian region," stated Chet Howard, CEO of AXM Pharma, Inc.

Sunkist, http://www.sunkist.com, has been among the world's most recognized brands for more than 100 years. Worldwide, consumers consistently rank Sunkist in the top 90th percentile for attributes of quality, esteem, stature, vitality, relevance and differentiation. The Sunkist brand can be found in a variety of product categories, including popular soft drinks, fruit juices and fruit snacks. Sold in more than 50 countries, Sunkist branded products generate more than $2 billion in annual sales.

AXM Pharma's product line is as deep as it is diverse. AXM Pharma now has 8 vitamin and nutritional supplements marketed in China under the Sunkist trademark and expects to expand the product line significantly across Asia.

AXM Pharma Inc., http://www.axmpharma.com, through its wholly owned subsidiary, Werke Pharmaceuticals, Inc., is the 100% owner of AXM Pharma Shenyang, Inc. ("AXM Shenyang"), a Wholly Foreign Owned Enterprise ("WFOE") under the laws of the People's Republic of China. AXM Shenyang is located in the City of Shenyang, in the Province of Liaoning, China. AXM Shenyang and its predecessor company Shenyang Tianwei Pharmaceutical Factory, Ltd. ("STPF"), has an operating history of approximately 10 years. AXM Shenyang historically has been a manufacturer of proprietary and generic pharmaceutical products, which include injectables, capsules, tablets, liquids and medicated skin products for export and domestic Chinese sales. For additional information on AXM Pharma Inc, please visit http://www.iccinfo.com or call Investor Communications Company, LLC at 866 562 0134.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this news release include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products and prices. With respect to AXM, except for the historical information contained herein, the matters discussed in this news release are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, AXM's extremely limited operating history, uncertainties related to the Company's access to additional capital, competition and dependence on key management.

Contact Information

  • Contact Information:
    Tom Bostic
    Investor Communications Company, LLC
    (866) 562-0134